ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Ferenci, Péter; Bernstein, David; Lalezari, Jacob; E. Cohen, Daniel; Luo, Yan; Cooper, Curtis; Tam, Edward; Tato Marinho, Rui; Tsai, Naoky; Nyberg, Anders; Box, Terry; Younes, Ziad; Enayati, Pedram; Green, Sinikka; Baruch, Yaacov; Raj Bhandari, Bal; Alexandru Căruntu, Florin; Sepe, Thomas; Chulanov, Vladimir; Janczewska, Ewa; Rizzardini, Giuliano; Gervain, Judit; Planas, Ramón; Moreno, Christophe; Hassanein, Tarek; Xie, Wangang; King, Martin; Podsadecki, Thomas; Rajender Reddy, K.

doi:10.1056/nejmoa1402338

Public

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Published in New England Journal of Medicine • May 4, 2014

Authors:

Péter Ferenci

David Bernstein

Jacob Lalezari

Abstract

BACKGROUND: The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin has shown efficacy in inducing a sustained virologic response in a phase 2 study involving patients with hepatitis C virus (HCV) genotype 1 infection. We conducted two p...

Subject

Ombitasvir

Dasabuvir

Paritaprevir

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!